EST
NBIX icon

EA Series Trust’s Neurocrine Biosciences NBIX Stock Holding History

EA Series Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.6M Buy
+17,009
New +$1.66M 0.06% 485

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EA Series Trust's NBIX Position: Q2 2023 in Review

EA Series Trust opened a new position in Neurocrine Biosciences (NBIX) in Q2 2023: 17,009 shares worth $1.6M. The stake represents 0.06% of the portfolio and ranks #485 among its holdings.

456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • EA Series Trust held 17,009 shares of Neurocrine Biosciences worth $1.6M as of Q2 2023.
  • Neurocrine Biosciences was a new EA Series Trust position in Q2 2023.
  • Neurocrine Biosciences made up 0.06% of EA Series Trust's portfolio in Q2 2023, its #485 holding.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.